Stock Market Reviews

Read and share opinions on ARWR (Arrowhead Pharmaceuticals, Inc.) stock. Join MyTopStock.com to discover reviews, insights, and discussions from investors about this company's performance in the stock

Latest News

• Arrowhead Pharmaceuticals to Participate in Upcoming January 2026 Events
  Dec 23, 2025
• Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
  Dec 15, 2025
• Arrowhead price target raised to $80 from $52 at RBC Capital
  Dec 12, 2025
• Arrowhead Pharmaceuticals (ARWR) Valuation Check as ARO-MAPT Enters First Human Trial in Alzheimer’s Treatment
  Dec 10, 2025
• Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-MAPT for the Treatment of Alzheimer’s Disease and Other Tauopathies
  Dec 8, 2025
• Arrowhead Pharmaceuticals Receives FDA Breakthrough Therapy Designation for Plozasiran in Severe Hypertriglyceridemia
  Dec 2, 2025
• Arrowhead Pharmaceuticals to Participate in Upcoming December 2025 Conferences
  Dec 1, 2025
• ARWR: Multiple Data Readouts Ahead in 2026…
  Dec 1, 2025
• Arrowhead (ARWR) Hits 3-Year High on Strong Earnings, FDA Approval
  Nov 27, 2025
• Arrowhead Pharmaceuticals Inc (ARWR) Q4 2025 Earnings Call Highlights: FDA Approval and ...
  Nov 26, 2025
• Arrowhead Pharmaceuticals Reports 2025 Fiscal Year-End Results
  Nov 25, 2025
• Arrowhead Pharmaceuticals Earns $200 Million Milestone Payment from Sarepta Therapeutics
  Nov 24, 2025

ARWR News

• Arrowhead Pharmaceuticals to Participate in Upcoming January 2026 Events
  PASADENA, Calif., December 23, 2025--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following upcoming events:
  Dec 23, 2025
• Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
  PASADENA, Calif., December 15, 2025--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that as an inducement to entering into employment with the Company, on December 12, 2025, the Company’s Board of Directors approved "inducement" grants to 78 new employees under Rule 5635(c)(4) of the NASDAQ Listing Rules. The grants entitle employees, in aggregate, to receive up to 141,310 restricted stock units. The grants are outside the Company’s stockholder-approved equity incentive plans and
  Dec 15, 2025
• Arrowhead price target raised to $80 from $52 at RBC Capital
  RBC Capital raised the firm’s price target on Arrowhead (ARWR) to $80 from $52 and keeps an Outperform rating on the shares after meeting with its management team. The recent approval of Redemplo marks a key milestone for the organization and the company remains upbeat about the early commercial traction, the analyst tells investors in a research note. The stock has had a meaningful run recently, but the non-deal-roadshow strengthens the firm’s conviction that transition to a fully integrated Bi
  Dec 12, 2025
• Arrowhead Pharmaceuticals (ARWR) Valuation Check as ARO-MAPT Enters First Human Trial in Alzheimer’s Treatment
  Arrowhead Pharmaceuticals (ARWR) just started dosing patients in its Phase 1/2a trial for ARO-MAPT, an RNA interference therapy aimed at tauopathies like Alzheimer’s, and the stock has been reacting to that step into neurodegeneration. See our latest analysis for Arrowhead Pharmaceuticals. That neuro move lands on top of a big year for Arrowhead, with regulatory momentum around plozasiran and a packed conference schedule helping drive a roughly 250 percent year to date share price return and...
  Dec 10, 2025
• Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-MAPT for the Treatment of Alzheimer’s Disease and Other Tauopathies
  PASADENA, Calif., December 08, 2025--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it has dosed the first subjects in a Phase 1/2a clinical trial of ARO-MAPT, the company’s investigational RNA interference (RNAi) therapeutic being developed as a potential treatment for tauopathies including Alzheimer’s disease, a progressive neurodegenerative disease characterized by cognitive and functional decline. Alzheimer’s disease is the most common cause of dementia, affecting an est
  Dec 8, 2025
• Arrowhead Pharmaceuticals Receives FDA Breakthrough Therapy Designation for Plozasiran in Severe Hypertriglyceridemia
  PASADENA, Calif., December 02, 2025--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that the United States Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to investigational plozasiran as an adjunct to diet to reduce triglyceride (TG) levels in adults with severe hypertriglyceridemia (SHTG) (TG levels greater than or equal to 500 mg/dL). There are currently limited and inadequate treatment options for the millions of people globally living with SHT
  Dec 2, 2025
• ARWR: Multiple Data Readouts Ahead in 2026…
  By David Bautz, PhD NASDAQ:ARWR READ THE FULL ARWR RESEARCH REPORT Business Update Multiple Data Readouts Ahead in 2026 Following the recent approval of REDEMPLO ® for the treatment of patients with familial chylomicronemia syndrome (FCS), Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) is now a commercial-stage company and recently reported that the drug is available for patients only one week
  Dec 1, 2025
• Arrowhead Pharmaceuticals to Participate in Upcoming December 2025 Conferences
  PASADENA, Calif., December 01, 2025--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following upcoming events:
  Dec 1, 2025
• How Do Sarepta (SRPT)’s Enhanced Safety Moves Reflect Its Approach to Long-Term Risk Management?
  Earlier this week, Sarepta Therapeutics received FDA approval to begin dosing non-ambulant Duchenne muscular dystrophy patients in Cohort 8 of the ENDEAVOR study, evaluating an enhanced immunosuppression regimen with Elevidys, and announced continued progress in its Phase 1/2 study of SRP-1003 for type 1 myotonic dystrophy. An important insight is that Sarepta's safety-focused updates and advancing clinical pipeline come alongside milestone payments to Arrowhead Pharmaceuticals, underlining...
  Nov 28, 2025
• Arrowhead (ARWR) Hits 3-Year High on Strong Earnings, FDA Approval
  We recently published 10 Big Names Feasting on Gains Ahead of Thanksgiving. Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) is one of the best-performing stocks on Wednesday. Arrowhead Pharmaceuticals soared to a new three-year high on Wednesday, as investors took heart from its impressive earnings performance for the full fiscal year, alongside the Food and Drug Administration’s (FDA) […]
  Nov 27, 2025
• Arrowhead Pharmaceuticals (ARWR) Is Up 48.1% After First FDA Approval for siRNA Rare Disease Therapy
  In November 2025, Arrowhead Pharmaceuticals announced that the U.S. FDA approved REDEMPLO (plozasiran) as the first and only siRNA treatment for adults with familial chylomicronemia syndrome, utilizing the company's proprietary TRiM™ platform. This landmark FDA approval marks Arrowhead's transformation into a commercial-stage company and validates its technology, highlighting the future potential of RNAi therapies in rare disease markets. We'll examine how Arrowhead's first FDA approval may...
  Nov 27, 2025
• Why Arrowhead Pharmaceuticals Stock Surged by Over 23% Today
  These are historic days for the company, following its first FDA approval.
  Nov 27, 2025
• Sector Update: Health Care Stocks Softer Late Afternoon
  Health care stocks were lower late Wednesday afternoon, with the NYSE Health Care Index easing 0.1%
  Nov 26, 2025
• Arrowhead Pharmaceuticals Inc (ARWR) Q4 2025 Earnings Call Highlights: FDA Approval and ...
  Arrowhead Pharmaceuticals Inc (ARWR) achieves a milestone with FDA approval of Redemplo and secures a lucrative partnership with Novartis, despite facing financial and developmental challenges.
  Nov 26, 2025
• Novartis cuts hundreds of jobs; Novo’s dual-acting diabetes drug heading to Phase 3
  The layoffs affect Swiss manufacturing facilities. Elsewhere, the FDA pushed back an approval deadline and a mid-stage study showed Novo’s amycretin helps regulate blood sugar.
  Nov 26, 2025
• Sarepta's Stock Rises on Positive Updates on DM1 Therapy
  SRPT's stock jumps as its SRP-1003 study advances with a positive safety review and new dosing cohorts underway.
  Nov 25, 2025
• Arrowhead Pharmaceuticals Reports 2025 Fiscal Year-End Results
  PASADENA, Calif., November 25, 2025--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced financial results for its 2025 fiscal year ended September 30, 2025. The Company is hosting a conference call today, November 25, 2025, at 4:30 p.m. ET to discuss the results.
  Nov 25, 2025
• Sarepta Provides Progress Update for SRP-1003, its Investigational siRNA treatment for Myotonic Dystrophy Type 1
  CAMBRIDGE, Mass., November 24, 2025--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today shared progress in the Phase 1/2 multiple ascending dose (MAD) clinical study of SRP-1003 (formerly ARO-DM1), an investigational small interfering RNA (siRNA) therapeutic for the treatment of type 1 myotonic dystrophy (DM1).
  Nov 24, 2025
• Arrowhead Pharmaceuticals Earns $200 Million Milestone Payment from Sarepta Therapeutics
  PASADENA, Calif., November 24, 2025--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it has earned a $200 million milestone payment from Sarepta Therapeutics (NASDAQ: SRPT). The milestone was earned when Arrowhead achieved the second development milestone event in a Phase 1/2 clinical study of ARO-DM1, also called SRP-1003, an investigational RNA interference (RNAi) therapeutic for the treatment of type 1 myotonic dystrophy (DM1), the most common adult-onset muscular dystroph
  Nov 24, 2025
• How Analyst Views Are Shifting as Arrowhead Pharmaceuticals Enters a New Phase of Growth
  Arrowhead Pharmaceuticals' fair value estimate has recently risen from $47.50 to $55.00 per share, signaling an improved outlook following the FDA approval of Redemplo. This updated price target reflects growing optimism about the company's commercial potential and its position in the market as it transitions to a fully commercial organization. Stay tuned to see how you can keep up with the evolving story as new milestones and analyst perspectives emerge. Analyst Price Targets don't always...
  Nov 20, 2025
• Analyzing Arrowhead Pharmaceuticals After Doubling in Price With RNA Therapy Breakthroughs
  Ever wondered if Arrowhead Pharmaceuticals’ meteoric rise means the best value is behind it, or if there is still room to capitalize? Let’s break down whether now is actually a good time to buy in. After doubling in price over the last year with a 108.3% gain and boasting a massive 98.3% return so far this year, the stock’s momentum is hard to ignore, despite some recent short-term volatility. Much of this price action has been fueled by encouraging clinical trial updates and partnerships...
  Nov 20, 2025
• A Look at Arrowhead Pharmaceuticals’s Valuation Following FDA Approval of First siRNA Therapy for Rare Disease
  Arrowhead Pharmaceuticals (ARWR) has just gained FDA approval for REDEMPLO, its first-ever approved drug and the first siRNA therapy available for familial chylomicronemia syndrome. This regulatory milestone marks the transition of Arrowhead into commercial-stage operations. See our latest analysis for Arrowhead Pharmaceuticals. The FDA approval has put a spotlight on Arrowhead Pharmaceuticals, with the 98% year-to-date share price return reflecting growing optimism around its commercial...
  Nov 20, 2025
• ARWR: REDEMPLO® Approved by FDA for the Treatment of FCS…
  By David Bautz, PhD NASDAQ:ARWR READ THE FULL ARWR RESEARCH REPORT Business Update REDEMPLO® Approved by FDA On November 18, 2025, Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) announced that the U.S. Food and Drug Administration (FDA) has approved REDEMPLO (plozasiran) as a treatment for adults suffering from familial chylomicronemia syndrome (FCS). This is the first approved product utilizing
  Nov 19, 2025
• Arrowhead nets first commercial win as siRNA drug garners FDA approval
  Redemplo’s approval in familial chylomicronemia syndrome places the drug in competition with Ionis’ Tryngolza.
  Nov 19, 2025
• Sector Update: Health Care Stocks Rise Late Afternoon
  Health care stocks rose late Tuesday afternoon, with the NYSE Health Care Index up 0.3% and the Heal
  Nov 18, 2025
• Arrowhead Pharmaceuticals Announces FDA Approval of REDEMPLO® (plozasiran) to Reduce Triglycerides in Adults with Familial Chylomicronemia Syndrome (FCS)
  PASADENA, Calif., November 18, 2025--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that the U.S. Food and Drug Administration (FDA) has approved REDEMPLO (plozasiran), a small interfering RNA (siRNA) medicine, as an adjunct to diet to reduce triglycerides in adults with familial chylomicronemia syndrome (FCS). FCS is a severe, rare disease, with an estimated 6,500 people in the U.S. living with genetic or clinical FCS, characterized by triglyceride levels that can be 10 to 100 t
  Nov 18, 2025
• RNAi biotech Arrowhead wins first FDA approval
  The clearance of Redemplo for a rare genetic disorder marks Arrowhead’s transition, after two decades, into a commercial-stage company and sets up a turf war with Ionis Pharmaceuticals.
  Nov 18, 2025
• Arrowhead Pharmaceuticals to Webcast Fiscal 2025 Year-End Results
  PASADENA, Calif., November 06, 2025--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it will host a webcast and conference call on November 25, 2025, at 4:30 p.m. ET to discuss its financial results for the 2025 fiscal year ended September 30, 2025.
  Nov 6, 2025
• Arrowhead Pharmaceuticals to Participate in Upcoming November 2025 Conferences
  PASADENA, Calif., November 04, 2025--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following upcoming events:
  Nov 4, 2025
• Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
  PASADENA, Calif., October 28, 2025--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that as an inducement to entering into employment with the Company, on October 24, 2025, the Company’s Board of Directors approved "inducement" grants to 84 new employees under Rule 5635(c)(4) of the NASDAQ Listing Rules. The grants entitle employees, in aggregate, to receive up to 127,230 restricted stock units. The grants are outside the Company’s stockholder-approved equity incentive plans and v
  Oct 28, 2025
• How Arrowhead’s Evolving Story Is Shaping Analyst Views and Fair Value Targets
  Arrowhead Pharmaceuticals has seen its consensus analyst price target increase from $45 to $47.50 per share, reflecting growing confidence in the company's strategy and market positioning. This positive revision comes as analysts weigh Arrowhead's cost advantages and expanding gross margins in addition to recent developments in its external partnerships. Stay tuned to discover how investors and analysts are tracking these evolving factors to stay ahead of changes in Arrowhead's investment...
  Oct 23, 2025
• Complement 3 Glomerulopathy Market Poised for Phenomenal Expansion at a CAGR of 37.2% During the Forecast Period (2025–2034) Owing to the Launch of Promising Therapies Targeting C3, C5, MASP-3, and RNAi | DelveInsight
  The complement 3 glomerulopathy market is poised for steady growth, driven by increasing disease awareness, advances in complement pathway research, and rising diagnostic rates. The lack of approved targeted therapies has spurred significant R&D investment in complement inhibitors and novel biologics. Pipeline therapies such as KP104 (Kira Pharmaceuticals), Zaltenibart (Omeros Corporation), Ruxoprubart (NovelMed Therapeutics), ARO-C3 (Arrowhead Pharmaceuticals), and others are expected to reshap
  Oct 22, 2025
• Arrowhead Pharmaceuticals Announces Closing of Global License and Collaboration Agreement with Novartis
  PASADENA, Calif., October 21, 2025--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that a global licensing and collaboration agreement with Novartis, previously announced on September 2, 2025, has now closed. Closing of the transaction was subject to the expiration or termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 and other customary conditions.
  Oct 21, 2025
• Arrowhead Pharmaceuticals Files CTA for Investigational ARO-DIMER-PA – the First Dual Functional RNAi Therapeutic for the Treatment of Mixed Hyperlipidemia
  PASADENA, Calif., October 07, 2025--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it has filed a request for regulatory clearance to initiate a Phase 1/2a clinical trial of ARO-DIMER-PA, the company’s investigational RNA interference (RNAi) therapeutic being developed as a potential treatment for atherosclerotic cardiovascular disease (ASCVD) due to mixed hyperlipidemia. ARO-DIMER-PA is designed to silence expression of the proprotein convertase subtilisin kexin 9 (PCSK9) a
  Oct 7, 2025
• Sarepta (SRPT) on Soars 15.7% on 5th Day Ahead of Clinical Trial Results
  We recently published 10 Stocks With Double-Digit Upsides. Sarepta Therapeutics, Inc. (NASDAQ:SRPT) is one of the top performers on Thursday. Sarepta Therapeutics extended its winning streak to a 5th consecutive day on Thursday, surging 15.68 percent to close at $22.35 apiece as investors repositioned portfolios ahead of the upcoming preliminary results for a drug clinical […]
  Oct 3, 2025
• Arrowhead Pharmaceuticals, Inc.'s (NASDAQ:ARWR) Intrinsic Value Is Potentially 72% Above Its Share Price
  Key Insights Arrowhead Pharmaceuticals' estimated fair value is US$59.37 based on 2 Stage Free Cash Flow to Equity...
  Oct 1, 2025
• Arrowhead Pharmaceuticals Files Complaint for Declaratory Judgment Against Ionis Pharmaceuticals
  PASADENA, Calif., September 11, 2025--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that yesterday it filed a Complaint for Declaratory Judgment in the United States District Court for the District of Delaware against Ionis Pharmaceuticals, Inc., to declare that Ionis’s United States Patent No. 9,593,333 ("the ’333 patent") is invalid and not infringed by Arrowhead’s planned commercialization of investigational plozasiran, which is under FDA review. Arrowhead intends to vigorous
  Sep 11, 2025
• H.C. Wainwright Reiterated a Buy on Arrowhead Pharmaceuticals (ARWR)
  Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) is one of the Best Stocks to Buy for the Next 3 Months According to Hedge Funds. On September 2, Patrick Trucchio from H.C. Wainwright reiterated a Buy rating on Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) with a price target of $80. The analyst noted the company’s recent deal with Novartis as a […]
  Sep 10, 2025
• Arrowhead Pharmaceuticals Requests Regulatory Clearance to Initiate Phase 1/2a Study of ARO-MAPT for the Treatment of Alzheimer’s Disease and Other Tauopathies
  PASADENA, Calif., September 10, 2025--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it has filed a request for regulatory clearance to initiate a Phase 1/2a clinical trial of ARO-MAPT, the company’s investigational RNA interference (RNAi) therapeutic being developed as a potential treatment for tauopathies including Alzheimer’s disease, a progressive neurodegenerative disease characterized by cognitive and functional decline. Alzheimer’s disease is the most common cause of
  Sep 10, 2025
• Why Shares in Arrowhead Pharmaceuticals Surged on News of a Novartis Deal
  The announcement of a landmark deal with a pharmaceutical giant validates Arrowhead's technology.
  Sep 5, 2025
• Arrowhead Lands Billion-Dollar Biotech Deal: Stock Soars Double-Digits
  ARWR Jumps as Novartis Bets Big on Parkinson's Therapy
  Sep 3, 2025
• ARWR: Signs Collaboration Agreement with Novartis with $200 Million Upfront…
  By David Bautz, PhD NASDAQ:ARWR READ THE FULL ARWR RESEARCH REPORT Business Update Signs Collaboration Agreement with Novartis On September 2, 2025, Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) announced a global collaboration and licensing agreement with Novartis (NYSE:NVS) for ARO-SNCA, a preclinical stage siRNA candidate that targets alpha-synuclein for the treatment of synucleinopathies
  Sep 2, 2025
• Novartis thinks Arrowhead brain drug can succeed where others couldn’t
  A licensing deal worth at least $200 million will give Novartis access to a preclinical RNA medicine designed to combat diseases like Parkinson’s.
  Sep 2, 2025
• Arrowhead Pharmaceuticals and Novartis Enter into a Global License and Collaboration Agreement
  PASADENA, Calif., September 02, 2025--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced a global licensing and collaboration agreement with Novartis for ARO-SNCA, Arrowhead’s preclinical stage siRNA therapy against alpha-synuclein for the treatment of synucleinopathies, such as Parkinson’s Disease, and for other additional collaboration targets that will utilize Arrowhead’s proprietary Targeted RNAi Molecule (TRiM™) platform. Upon closing, Arrowhead will receive $200 million as an u
  Sep 2, 2025
• Arrowhead Pharma Jumps After Inking A Deal Worth Up To $2.2 Billion
  Arrowhead Pharmaceuticals and Novartis inked a licensing deal Tuesday for an experimental Parkinson's drug, sending Arrowhead stock surging.
  Sep 2, 2025
• Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) institutional owners may be pleased with recent gains after 7.6% loss over the past year
  Key Insights Significantly high institutional ownership implies Arrowhead Pharmaceuticals' stock price is sensitive to...
  Sep 1, 2025
• Arrowhead Pharmaceuticals to Participate in Upcoming September 2025 Conferences
  PASADENA, Calif., August 27, 2025--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following upcoming events:
  Aug 27, 2025

ARWR Reviews

• BearEater

  Dec 31, 2025

  $ARWR With a robust pipeline of innovative therapies aimed at addressing unmet medical needs, this company is making significant strides in the biotechnology arena. Its focus on advancing treatments for serious diseases sets a promising trajectory for growth.

  Buy

• DividendJunkie

  Dec 31, 2025

  $ARWR Promises more than it can deliver—classic.

  Sell

• TickerTrickster

  Dec 30, 2025

  $ARWR This biotech's got potential to blow up, keep your eyes peeled!

  Buy

• TradeProtocol

  Dec 30, 2025

  $ARWR This company is the secret sauce in the drug development world, cooking up treatments like a chef whipping up a masterpiece!

  Buy

• BearBreaker

  Dec 30, 2025

  $ARWR This one’s been a rollercoaster, and not the fun kind.

  Sell

• CodeAndCapital

  Dec 29, 2025

  $ARWR They’re exploring the wild frontier of medicine like an adventurous sci-fi hero—let’s hope they don’t need a spaceship!

  Buy

• CryptoCobra

  Dec 29, 2025

  $ARWR This company is like the mad scientist of medicine—experimenting for the win! Just hope it doesn’t create a monster!

  Buy

• ChartNomad

  Dec 29, 2025

  $ARWR This company is on the brink of groundbreaking advancements, making every earnings report a nail-biter. Will their innovations pay off or plunge into oblivion? The tension is palpable!

  Buy

• MoneyMage

  Dec 28, 2025

  $ARWR Promising treatments? More like promising disappointments.

  Sell

• TheQuantEdge

  Dec 28, 2025

  $ARWR This biotech is racing against time, and the stakes couldn't be higher! Breakthroughs could be just around the corner, but so could major setbacks. What happens next is anyone's guess!

  Buy

• OptionOutlaw

  Dec 28, 2025

  $ARWR Another one that’s just spinning its wheels.

  Sell

• ShortSqueezeX

  Dec 28, 2025

  $ARWR Like a science experiment gone right! They’re crafting innovative therapies that sound like something out of a superhero movie.

  Buy

• ProfitVortex

  Dec 28, 2025

  $ARWR If this stock were a superhero, its superpower would be curing all your healthcare worries—cape optional!

  Buy

• OptionOverlord

  Dec 28, 2025

  $ARWR This company is like the superhero of the pharma world—saving the day one gene at a time. Cape not included.

  Buy

• CapitalFrame

  Dec 27, 2025

  $ARWR With innovative approaches to tackling genetic diseases, this company is on the cutting edge of biotechnology. Their pipeline's potential to address unmet medical needs is promising for the healthcare landscape.

  Buy

• BullRaid

  Dec 27, 2025

  $ARWR Another biotech with more hype than substance.

  Sell

• WallStreetVandal

  Dec 27, 2025

  $ARWR Great concept, too bad it's not a reality.

  Sell

• TheQuantEdge

  Dec 26, 2025

  $ARWR In the race against time for innovative treatments, this company seems to teeter on the edge of breakthrough or disappointment. Can they cross the finish line before losing steam?

  Sell

• OptionNomad

  Dec 26, 2025

  $ARWR With groundbreaking advancements on the horizon, the pressure is on to deliver results! Investors are anxious for updates, and one wrong step could send shockwaves through the market!

  Buy

• ShortSavage

  Dec 26, 2025

  $ARWR With breakthroughs at the horizon, the stakes are high! Will they capitalize on these advancements, or will this be a missed opportunity?

  Buy

• GainsOverBrains

  Dec 26, 2025

  $ARWR This one's like a secret weapon, ready to strike!

  Buy

• AlphaVandal

  Dec 25, 2025

  $ARWR Pharmaceuticals are always risky, but this one screams desperation.

  Sell

• SignalStriker

  Dec 24, 2025

  $ARWR With the biotech sector buzzing, this company seems poised for a breakthrough, but the unpredictability keeps everyone on their toes. Will it be a triumph or tragedy? The stakes couldn’t be higher!

  Buy

• QuantSpecter

  Dec 23, 2025

  $ARWR In the volatile world of pharmaceuticals, will groundbreaking research lead to success or disappointment? Each trial brings its own set of hurdles, and one misstep could change everything. The atmosphere is charged!

  Buy

• RiskVandal

  Dec 23, 2025

  $ARWR Chasing dreams with no real results in sight.

  Sell

• BearMarketSurvivor

  Dec 22, 2025

  $ARWR They got the cure game on lock, don’t sleep on this!

  Buy

• GammaSlayer

  Dec 22, 2025

  $ARWR Another biotech with more hope than results. How refreshing.

  Sell

• RiskAssassin

  Dec 21, 2025

  $ARWR This company is navigating the rocky waters of biotech with potential breakthroughs that could either skyrocket its value or send it plummeting. It's a wild ride, and the pressure is palpable!

  Buy

• StockSpecter

  Dec 21, 2025

  $ARWR Pharmaceutical innovation or just more empty promises?

  Sell

• RiskRanger

  Dec 21, 2025

  $ARWR This company is like the mad scientist of health—mixing up potions to make your DNA do backflips!

  Buy

• TradeHex

  Dec 21, 2025

  $ARWR This innovative biotechnology company is dedicated to advancing treatments through RNA-targeted therapies. Their steadfast commitment to research and impressive clinical results could signify a transformative impact in the pharmaceutical industry.

  Buy

• TrendStalker

  Dec 20, 2025

  $ARWR Just another shot in the dark, good luck with that.

  Sell

• MarketMemeLord

  Dec 20, 2025

  $ARWR Playin' with the big dogs in pharma, keep your eyes peeled!

  Buy

• BearWithMe

  Dec 20, 2025

  $ARWR Crackin' the code in biotech, these folks are on the cutting edge.

  Buy

• QuantRift

  Dec 20, 2025

  $ARWR With advancements in biotechnology, this company is at the forefront of developing groundbreaking therapies. Its innovative research pipeline holds promise for addressing significant medical needs, positioning it well for future success.

  Buy

• FiscalFury

  Dec 19, 2025

  $ARWR If this stock were a superhero, it would totally be the one saving the day with some groundbreaking meds—cape and all!

  Buy

• TradeProtocol

  Dec 19, 2025

  $ARWR This company is like a magician with genes, making diseases disappear faster than your phone battery at a party!

  Buy

• HedgeKnight

  Dec 19, 2025

  $ARWR This company is like a wizard with a wand, casting spells in the lab—who knows what kind of potion they’ll brew up next?

  Buy

• GainMachine

  Dec 18, 2025

  $ARWR This stock is the underdog of the pharma world. It’s like rooting for the last kid picked in gym class!

  Buy

• CapitalHex

  Dec 17, 2025

  $ARWR This firm is at the forefront of groundbreaking research in the pharmaceutical industry, with potential game-changing therapies that could significantly impact treatment options. Their innovative pipeline holds great promise.

  Buy

• MoonBagz

  Dec 17, 2025

  $ARWR Playing the long game, but this one’s got the chops to surprise you!

  Buy

• EquityPulse

  Dec 17, 2025

  $ARWR The scientific breakthroughs are exciting, but can they deliver results? With high hopes comes great pressure, and investors are biting their nails in anticipation!

  Buy

• HedgeKnight

  Dec 17, 2025

  $ARWR This company is treating diseases like they’re last week’s homework—time to get rid of them!

  Buy

• ChartSaber

  Dec 16, 2025

  $ARWR This one's got the future locked down, real breakthrough vibes.

  Buy

• TradeReckoner

  Dec 16, 2025

  $ARWR Another biotech hope? Prepare for disappointment.

  Sell

• MarginDagger

  Dec 15, 2025

  $ARWR This innovative company is at the forefront of developing transformative therapies, showcasing a strong commitment to advancing healthcare solutions. With promising candidates in clinical trials, it has the potential to significantly impact patient outcomes in critical diseases.

  Buy

• ManiaBroker

  Dec 15, 2025

  $ARWR Like a sci-fi movie but with real-life results; expect plot twists that could change the world!

  Buy

• CandleFreak

  Dec 15, 2025

  $ARWR With a strong focus on groundbreaking therapies, this firm is at the forefront of biopharmaceutical advancements. Its pipeline showcases promising developments that could transform patient care.

  Buy

• FiscalBinary

  Dec 15, 2025

  $ARWR Bulls pressing their advantage.

  Buy

• HedgeMeNot

  Dec 14, 2025

  $ARWR They’re in the lab cookin’ up gold, watch for the big reveal!

  Buy

• YieldWarden

  Dec 14, 2025

  $ARWR With innovative potential looming on the horizon, the excitement is tangible. Yet, one wrong step could lead to a drop off a cliff—hold tight while watching the market closely!

  Sell

• DiamondHandz

  Dec 13, 2025

  $ARWR Biotech ballers makin’ moves, but watch out, could be hit or miss out there!

  Sell

• TradePulse

  Dec 13, 2025

  $ARWR Amid groundbreaking advancements and fierce competition, this biotechnology company is hanging by a thread, with potential breakthroughs that could either skyrocket or plummet.

  Buy

• TradePhantom

  Dec 13, 2025

  $ARWR Aiming for the moon but still stuck in orbit.

  Sell

• PnLReaper

  Dec 13, 2025

  $ARWR Everything leans bullish here.

  Buy

• MarginMythic

  Dec 12, 2025

  $ARWR Bullish multi-timeframe alignment.

  Buy

• MoneyMage

  Dec 12, 2025

  $ARWR Price holding above key levels.

  Buy

• TheStockKnight

  Dec 11, 2025

  $ARWR Weak chart with clear sell signals.

  Sell

• StockNova

  Dec 11, 2025

  $ARWR No sign of buyers stepping in.

  Sell

• MarketGlitch

  Dec 11, 2025

  $ARWR Charts look incredibly strong.

  Buy

• PriceBreaker

  Dec 11, 2025

  $ARWR Price expansion coming soon.

  Buy

• Stonks4Days

  Dec 11, 2025

  $ARWR Pushing boundaries in biotech, they might just change the game!

  Buy

• FOMOKing

  Dec 10, 2025

  $ARWR Got some heat, might just catch fire if it plays it right.

  Buy

• ChartFang

  Dec 10, 2025

  $ARWR This organization is at the forefront of groundbreaking advancements in healthcare, making significant strides that could reshape treatment paradigms and enhance patient outcomes.

  Buy

• TradeNinja

  Dec 9, 2025

  $ARWR Relative strength extremely strong.

  Buy

• ChartSaber

  Dec 9, 2025

  $ARWR Big sellers smashing bids.

  Sell

• TheGainReaper

  Dec 9, 2025

  $ARWR Falling behind while others pass them by effortlessly.

  Sell

• ProfitFang

  Dec 7, 2025

  $ARWR With a pioneering approach to genetic medicine, this pharmaceutical firm is at the forefront of transformative therapies. Their pipeline shows promise for addressing chronic conditions and could reshape treatment paradigms in the coming years.

  Buy

• FUDCrusher

  Dec 7, 2025

  $ARWR Got breakthroughs droppin’, this one's on the rise, no doubt!

  Buy

• ShortAndProud

  Dec 7, 2025

  $ARWR Pharma flexing big dreams, watch for the glow up!

  Buy

• PnLReaper

  Dec 6, 2025

  $ARWR With a strong focus on gene editing and innovative therapies, this biotechnology company is working on groundbreaking treatments that could redefine healthcare solutions.

  Buy

• QuantumBroker

  Dec 5, 2025

  $ARWR This company's pioneering work in RNA-targeted therapies could be a game changer, but the market is volatile! With increasing competition, one wrong move could spell disaster. Keep a close eye on the upcoming trial results.

  Buy

• ChartCrusher

  Dec 5, 2025

  $ARWR A biotech that's more hype than hope. Good luck with that.

  Sell

• ProfitVortex

  Dec 5, 2025

  $ARWR This company’s approach to medicine is like finding Wi-Fi in a coffee shop—unexpectedly awesome and super helpful!

  Buy

• BullishBerserker

  Dec 5, 2025

  $ARWR A promising outlook, but it’s a heart-pounding experience watching the ups and downs! Can it maintain this momentum, or are we in for another tough round?

  Sell

• RocketDividend

  Dec 5, 2025

  $ARWR Doing crazy stuff in the lab, could be a game changer!

  Buy

• TradeReckoner

  Dec 4, 2025

  $ARWR Downside continuation formation.

  Sell

• CashClown

  Dec 4, 2025

  $ARWR Bullish drift upward.

  Buy

• TheQuantEdge

  Dec 4, 2025

  $ARWR Continuation to downside expected.

  Sell

• DiamondHandz

  Dec 4, 2025

  $ARWR Bearish liquidity hunt underway.

  Sell

• YieldVector

  Dec 4, 2025

  $ARWR Market weakness accelerating.

  Sell

• ShortSavior

  Dec 3, 2025

  $ARWR Pharmaceutical wonders that lead to nada.

  Sell

• TheChartCode

  Dec 2, 2025

  $ARWR If this company were a superhero, it would be the one inventing cool gadgets that actually heal people. Sign me up for that adventure!

  Buy

• BearHunter

  Dec 2, 2025

  $ARWR This company's got the right idea – always looking for ways to hack your biology. Just don’t forget to include snacks in your life algorithm!

  Buy

• VolatilityStrike

  Dec 1, 2025

  $ARWR The advancements in its proprietary technology have the potential to revolutionize treatment options in critical areas. Continued research and development efforts may yield promising results for its future endeavors.

  Buy

• StockStrider

  Dec 1, 2025

  $ARWR Focusing on cutting-edge genetic medicines, this firm is well-positioned to leverage advancements in biotechnology. Its commitment to innovation could lead to transformative treatments in the coming years.

  Buy

• StonkDestroyer

  Dec 1, 2025

  $ARWR More promises than progress; sounds familiar.

  Sell

• ChartFang

  Nov 30, 2025

  $ARWR This firm is at the forefront of biopharmaceutical innovation, focusing on cutting-edge therapies that address unmet medical needs. Their ongoing research and development efforts highlight their potential to transform healthcare.

  Buy

• CapitalHex

  Nov 30, 2025

  $ARWR This biotechnology company's cutting-edge research in genetic therapies holds substantial promise, potentially revolutionizing treatment options for various diseases and attracting significant investor interest.

  Buy

• HODLzilla

  Nov 30, 2025

  $ARWR Keepin' it real, this biotech could hit the jackpot!

  Buy

• MarketMarauder

  Nov 30, 2025

  $ARWR Tries hard to be innovative, but often trips over its own feet.

  Sell

• LiquidLegend

  Nov 30, 2025

  $ARWR They’re working on revolutionary treatments—maybe one day I can get a shot for procrastination?

  Buy

• BuyLowBoi

  Nov 30, 2025

  $ARWR Pharma's bringing heat, got my attention for sure!

  Buy

• TheQuantEdge

  Nov 29, 2025

  $ARWR The pharmaceutical landscape is a battlefield, and every breakthrough feels like a double-edged sword. Can they emerge victorious, or will the competition steal the spotlight?

  Buy

• TradeBlitz

  Nov 29, 2025

  $ARWR This company is like that friend who always brings snacks to the party—everyone wants them around!

  Buy

• CodeTrader

  Nov 28, 2025

  $ARWR With groundbreaking therapies in development, this biopharma feels like it’s on the brink of something huge. But will they stumble before the finish line? The suspense is intense!

  Buy

• MarginMythic

  Nov 27, 2025

  $ARWR Amid groundbreaking research, this biotech is under immense pressure to deliver results. One miscalculation could lead to a dramatic plunge—tension is high!

  Sell

• GainVector

  Nov 27, 2025

  $ARWR With ground-breaking developments in gene-editing and therapeutic technologies, this firm is setting new benchmarks in the pharmaceutical industry. Their pipeline of potential treatments could lead to substantial breakthroughs.

  Buy

• DividendVortex

  Nov 27, 2025

  $ARWR This biotechnology firm is at the forefront of developing novel therapies aimed at serious diseases. Their promising pipeline and strategic collaborations indicate a bright outlook as they navigate the evolving healthcare landscape.

  Buy

• EarningsEcho

  Nov 26, 2025

  $ARWR With their revolutionary ideas, they’re like the mad scientists of the pharma world—just without crazy hair!

  Buy

• ShortSqueezeX

  Nov 26, 2025

  $ARWR This one’s like the quiet kid in class who suddenly becomes a rock star—totally unexpected and seriously impressive when they get the spotlight!

  Buy

• GainVector

  Nov 26, 2025

  $ARWR Focusing on innovative solutions for genetic diseases, this entity is making strides in targeted therapies. Their ongoing research and development efforts reflect a strong commitment to advancing healthcare and improving patient outcomes.

  Buy

• BullishBard

  Nov 26, 2025

  $ARWR This company is like the superhero of pharmaceuticals—saving lives one innovative treatment at a time. Capes not included!

  Buy

• PaperHandsGone

  Nov 25, 2025

  $ARWR Innovatin' in the health game, these folks are cookin' up some next-level solutions!

  Buy

• EarningsEcho

  Nov 23, 2025

  $ARWR This company is like a magician; pulling off tricks in the biotech world that leave everyone wondering how they did it!

  Buy

• TradeProtocol

  Nov 23, 2025

  $ARWR These folks are working on some wild science—if they were a superhero, they’d definitely have a lab coat as their cape!

  Buy

• VolatilityNomad

  Nov 22, 2025

  $ARWR Chasing a miracle while others sprint ahead.

  Sell

• MarketNomad

  Nov 22, 2025

  $ARWR Pharma innovations… for people who don’t mind waiting forever.

  Sell

• CapitalNova

  Nov 22, 2025

  $ARWR With a strong pipeline of innovative therapies, this biotechnology firm is at the forefront of precision medicine. Its ongoing research and collaborations are promising indicators of future revenue potential.

  Buy

• MarketSavage

  Nov 22, 2025

  $ARWR This company seems to be chasing after shadows, good luck with that.

  Sell

• TheEarningsBeast

  Nov 21, 2025

  $ARWR This crew is like the superheroes of health, saving lives and maybe becoming my next favorite comic book franchise. Capes optional!

  Buy

• QuantAssault

  Nov 20, 2025

  $ARWR This stock is like a superhero in a lab coat—fighting for breakthroughs and saving the day!

  Buy

• QuantQuest

  Nov 20, 2025

  $ARWR Imagine a lab coat wearing, science-loving stock that makes the coolest inventions. This one’s got 'mad scientist' energy!

  Buy

• TradeRebel

  Nov 18, 2025

  $ARWR With each scientific breakthrough comes a wave of hope, but are we chasing illusions? The urgency to succeed is palpable, and the clock is ticking for those invested in this race!

  Buy

• GainsOverBrains

  Nov 18, 2025

  $ARWR Pharma game tight, watch for the next big hit!

  Buy

• DividendVandal

  Nov 17, 2025

  $ARWR This biotechnology company is on the cutting edge of innovative treatments, with a strong pipeline that reflects its commitment to addressing serious health challenges.

  Buy

• MarketMyth

  Nov 17, 2025

  $ARWR Leading the charge in gene editing technologies, this organization is unlocking new possibilities in the treatment of genetic diseases, showcasing its innovative potential.

  Buy

• TheAlphaDagger

  Nov 17, 2025

  $ARWR With innovative approaches in the biotech arena, will this company soar or stumble? The tension is thick as each report rolls in!

  Sell

• EquityEnigma

  Nov 17, 2025

  $ARWR In the race for revolutionary treatments, they might be onto something big! But with so many twists and turns in biotech, will they hit a roadblock or soar higher?

  Buy

• CashWraith

  Nov 17, 2025

  $ARWR The tension is thick as whispers circulate about breakthroughs and setbacks. Investors hold their breath, waiting for the next move. It's an excruciating watch, and the stakes keep climbing!

  Sell

• ByteBull

  Nov 15, 2025

  $ARWR This company is like a superhero for your cells—fighting off bad guys and making diseases disappear! 🦸‍♂️🦠

  Buy

• CashClown

  Nov 15, 2025

  $ARWR Innovations coming through, this biotech could break the mold!

  Buy

• RiskRaider

  Nov 14, 2025

  $ARWR More like Arrowhead Pharmaceuticals, Inc. of Disappointment.

  Sell

• HODLWarrior

  Nov 14, 2025

  $ARWR Pushing boundaries and breaking barriers, can't sleep on this!

  Buy

• TrendStalker

  Nov 14, 2025

  $ARWR It's just a matter of time before this one sinks.

  Sell

• TrendScript

  Nov 13, 2025

  $ARWR Focused on pioneering therapeutic solutions, this biotech firm stands at the forefront of innovation. Its robust pipeline suggests significant potential for breakthroughs that could reshape treatment options in critical health areas.

  Buy

• HedgeMeNot

  Nov 12, 2025

  $ARWR They’re cooking up some wild stuff in the lab, watch out!

  Buy

• OptionOverlord

  Nov 12, 2025

  $ARWR This stock is like the unexpected plot twist in a movie – you never know what's coming, but it might just leave you shocked!

  Buy

• WallStreetRogue

  Nov 12, 2025

  $ARWR Biotech stocks are a wild ride, and this one is no exception! Breakthroughs are on the horizon, but can they push through the hurdles?

  Buy

• RocketDividend

  Nov 12, 2025

  $ARWR They’re cookin' up some serious biotech, stay tuned!

  Buy

• RiskVandal

  Nov 12, 2025

  $ARWR Another biotech with more hype than results. Yawn.

  Sell

• GainMachine

  Nov 12, 2025

  $ARWR This company is like a ninja with a PhD in biotechnology – stealthy, smart, and totally ready to take on some serious health challenges!

  Buy

• CodeTrader

  Nov 12, 2025

  $ARWR The biotech arena is ruthless, and this company's got to keep innovating to stay alive. Will they hit the jackpot or face a setback?

  Sell

• CashOverload

  Nov 11, 2025

  $ARWR Guess innovations don't pay off for you, huh?

  Sell

• TraderFury

  Nov 11, 2025

  $ARWR The market is buzzing with potential, but can this biotech survive the trials? Every breakthrough could mean life or death, and stakes couldn't be higher!

  Buy

• MarketMyth

  Nov 10, 2025

  $ARWR This organization is at the forefront of developing cutting-edge therapies that target genetic diseases, showcasing its commitment to innovation and potential for significant impact in the pharmaceutical landscape.

  Buy

• ShortAndProud

  Nov 10, 2025

  $ARWR Pushing the needle in biopharma—gotta respect the grind!

  Buy

• StonkSlayer

  Nov 10, 2025

  $ARWR Put on your lab coats, folks! They’re all about changing the game in medicine—let's hope they don’t turn anyone into a science experiment!

  Sell

• PixelBroker

  Nov 10, 2025

  $ARWR They’re like the cool science nerds making life-saving potions. Who knew that science could be this epic!

  Buy

• TradeProtocol

  Nov 9, 2025

  $ARWR If this stock were a superhero, it would totally save the day—just don’t ask it to fix your WiFi!

  Buy

• StonkSamurai

  Nov 9, 2025

  $ARWR Pushing boundaries in health, they’re on the cutting edge!

  Buy

• TickerTakedown

  Nov 9, 2025

  $ARWR This company's got more ups and downs than a rollercoaster – hold on tight for the thrills!

  Buy

• TrendScript

  Nov 8, 2025

  $ARWR With a dedicated focus on gene silencing technology, this biopharmaceutical enterprise is on the forefront of revolutionary treatments. Its pipeline indicates strong potential for addressing significant health challenges.

  Buy

• TheGainReaper

  Nov 7, 2025

  $ARWR With their track record, you'd think they were allergic to success.

  Sell

• EquityPulse

  Nov 5, 2025

  $ARWR Whole market's giving 'we back baby' energy. If charts could talk, this one would say, 'Let's ride!'.

  Buy

• CapitalCreep

  Nov 2, 2025

  $ARWR residence cave should bear warning come is a strategy with not a confirmed hope

  Sell

• TickerTakedown

  Oct 13, 2025

  $ARWR Momentum so clean I'd frame this chart. Candle after candle -.

  Buy

• TradeBlaze

  Oct 12, 2025

  $ARWR crypto label come trend's warning than deader milk like aged

  Buy

• BullishBard

  Oct 11, 2025

  $ARWR If charts could talk, this one would say, 'Let's ride!' This chart looks like it just had an.

  Buy

• LazyQuant

  Oct 7, 2025

  $ARWR good to news allergic looks

  Sell

• RiskProtocol

  Oct 7, 2025

  $ARWR wild tight imo feels hedges lower range earnings energy nimble trap grind noise diamond now soon theta watching eyes cat heavy heavy

  Sell

• AlphaVandal

  Oct 7, 2025

  $ARWR soon-ish mode noise level-to-level trap eyes heavy patience wild fading levels earnings noise maybe diamond maybe now heavy volume sentiment money heavy weak clean cliff charts sauce

  Sell

• TradeBlitz

  Oct 5, 2025

  $ARWR I'm not saying it's mooning, but it's definitely packing a suitcase.

  Buy

• TickerTrickster

  Oct 5, 2025

  $ARWR beyond pain train express trend like repair broken regret smells

  Sell

• FiscalBinary

  Oct 5, 2025

  $ARWR If charts could talk, this one would say, 'Let's ride!' Green candles.

  Sell

• RiskReaper

  Oct 2, 2025

  $ARWR My portfolio's new hobby: losing gracefully. Someone please unplug the.

  Buy

• GainsGoblin

  Sep 27, 2025

  $ARWR falling this aged like faster my GPA milk than

  Sell

• RiskRanger

  Sep 25, 2025

  $ARWR Even my risk management is smiling today. Chart's climbing like.

  Sell

• ShortSavior

  Sep 20, 2025

  $ARWR hazard screams pay better investors chart

  Sell

• TheAlphaDagger

  Sep 19, 2025

  $ARWR If patience was a stock, I'd be rich by now. Market drama is better.

  Buy

• TradeSaber

  Sep 17, 2025

  $ARWR keeping feels soon spike earnings talking today cliff vol trend loud trend keeping watching heavy feels watching hedges session today

  Sell

• PortfolioFreak

  Sep 16, 2025

  $ARWR hard theta trigger lows heavy queued soon stops fast buzzing sentiment now soon humming noise talking keeping tape wild lower watching clean wild hands noise feels rip nimble steady

  Sell

• Stonks4Days

  Sep 15, 2025

  $ARWR bagholder loud on on tape nimble tape tape imo earnings mess levels macro theta spike city sauce levels wild

  Sell

• WallStreetWolf

  Sep 14, 2025

  $ARWR Market drama is better than Netflix lately. Honestly, I'm just here for the memes at this point.

  Buy

• ChartFang

  Aug 29, 2025

  $ARWR Chart's climbing like it heard good news from the universe. This volume.

  Buy

• AlgoAce

  Aug 21, 2025

  $ARWR Riding this wave with tears of joy and a side of.

  Buy

• TheFiscalShade

  Aug 17, 2025

  $ARWR I blinked and lost my lunch money. I'm emotionally diversified but financially.

  Buy

• ProfitLancer

  Aug 17, 2025

  $ARWR to green price candles clown action is 'ouch' chart

  Sell

• CryptoCobra

  Aug 17, 2025

  $ARWR imo tight steady go vibes heater soon alpha diamond charts wild clean crushing no whispers wild

  Buy

• ChartPhantom

  May 15, 2025

  $ARWR noise sentiment fast session bear patience spike ruggy today rough choppy tbh liquidity tape earnings buzzing bagholder hedges

  Sell

• YieldHunter

  Mar 3, 2025

  $ARWR feels check mode heavy today bull frankly flows buzzing printing here heavy it check dripping bull whoa

  Buy

• ProfitVortex

  Jan 2, 2025

  $ARWR alpha nimble on flows nimble hands soon-ish mode bid patience vol maybe today hard feels uptrend and

  Buy

• GammaGrind

  Oct 23, 2024

  $ARWR spike today on it check trend hedges soon-ish passed macro dripping

  Buy

• TradeRebel

  Oct 14, 2024

  $ARWR humming vol gains nasty staying clean imo alpha ath tight smart humming soon-ish

  Buy

• MarginMythic

  Aug 17, 2024

  $ARWR vol theta today bounce vol feels mode trigger smart tight beastly vibes level-to-level bull keeping oversold hedges trigger sentiment uptrend

  Buy

• BagholderPrime

  Jul 25, 2024

  $ARWR humming gains strong nasty breakout clear heavy imo sentiment crushing tape soon tape rocket eyes momentum check

  Buy

• BullRunBoi

  Jul 19, 2024

  $ARWR levels bear fading tax trigger wall hard volume hurts cliff patience clean charts today trigger humming maybe

  Sell

• CashCraze

  Jul 6, 2024

  $ARWR watching today noise clean frankly mooning vol it rocket tape hurts oversold feels passed here noise patience trend on

  Buy

• WallStreetWolf

  Feb 17, 2024

  $ARWR maybe noise watching range fast frankly look theta energy fast out candle whoa spike

  Sell

• MarketMatrix

  Dec 25, 2023

  $ARWR tax imo feels humming feels feels breakout wild tax king vol whoa hedges heat it soon king

  Buy

• AlgoAce

  Dec 4, 2023

  $ARWR tight feels broken rough vibes money today lows bagholder hard trigger

  Sell

• TheLongPlay

  Dec 1, 2023

  $ARWR check vol no mooning soon oversold heat level-to-level gains soon strong

  Buy

• ChartNomad

  Nov 24, 2023

  $ARWR tape sauce candle theta bleeding doom hedges trap vibes soon

  Sell